Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
HLA-DOA
Introduction
HLA class II histocompatibility antigen, DO alpha chain is a protein that in humans is encoded by the HLA-DOA gene.[1][2]
HLA-DOA belongs to the HLA class II alpha chain paralogues. HLA-DOA forms a heterodimer with HLA-DOB. The heterodimer, HLA-DO, is found in lysosomes in B cells and regulates HLA-DM-mediated peptide loading on MHC class II molecules. In comparison with classical HLA class II molecules, this gene exhibits very little sequence variation, especially at the protein level.[2]
References
References
- ↑ Young JA, Trowsdale J (Aug 1990). “The HLA-DNA (DZA) gene is correctly expressed as a 1.1 kb mature mRNA transcript”. Immunogenetics. 31 (5–6): 386–8. doi:10.1007/BF02115015. PMID 2370084.
- ↑ 2.0 2.1 “Entrez Gene: HLA-DOA major histocompatibility complex, class II, DO alpha”.
Further reading
Further reading
- Piatier-Tonneau D, Gastinel LN, Amblard F, et al. (1991). “Interaction of CD4 with HLA class II antigens and HIV gp120”. Immunogenetics. 34 (2): 121–8. doi:10.1007/BF00211424. PMID 1869305.
- Rosenstein Y, Burakoff SJ, Herrmann SH (1990). “HIV-gp120 can block CD4-class II MHC-mediated adhesion”. J. Immunol. 144 (2): 526–31. PMID 1967269.
- Bowman MR, MacFerrin KD, Schreiber SL, Burakoff SJ (1991). “Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibility complex molecules”. Proc. Natl. Acad. Sci. U.S.A. 87 (22): 9052–6. doi:10.1073/pnas.87.22.9052. PMC 55099. PMID 1978941.
- Rosen-Bronson S, Long EO (1991). “An unusual form of alternative splicing in the HLA-DNA gene”. Immunogenetics. 33 (2): 124–31. doi:10.1007/BF00210826. PMID 1999352.
- Jonsson AK, Rask L (1989). “Human class II DNA and DOB genes display low sequence variability”. Immunogenetics. 29 (6): 411–3. doi:10.1007/BF00375872. PMID 2499532.
- Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). “Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding”. Nature. 339 (6225): 548–51. doi:10.1038/339548a0. PMID 2543930.
- Diamond DC, Sleckman BP, Gregory T, et al. (1988). “Inhibition of CD4+ T cell function by the HIV envelope protein, gp120”. J. Immunol. 141 (11): 3715–7. PMID 2846691.
- Inoko H, Ando A, Kimura M, Tsuji K (1985). “Isolation and characterization of the cDNA clone and genomic clones of a new HLA class II antigen heavy chain, DO alpha”. J. Immunol. 135 (3): 2156–9. PMID 2991382.
- Trowsdale J, Kelly A (1986). “The human HLA class II alpha chain gene DZ alpha is distinct from genes in the DP, DQ and DR subregions”. EMBO J. 4 (9): 2231–7. PMC 554490. PMID 3000765.
- Andrieu JM, Even P, Venet A (1986). “AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications”. AIDS research. 2 (3): 163–74. doi:10.1089/aid.1.1986.2.163. PMID 3489470.
- Houlgatte R, Scarmato P, el Marhomy S, et al. (1994). “HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4”. J. Immunol. 152 (9): 4475–88. PMID 7512597.
- Chirmule N, McCloskey TW, Hu R, et al. (1995). “HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71)”. J. Immunol. 155 (2): 917–24. PMID 7541827.
- Rowell JF, Stanhope PE, Siliciano RF (1995). “Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC”. J. Immunol. 155 (1): 473–88. PMID 7602119.
- Chen YH, Böck G, Vornhagen R, et al. (1994). “HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41”. Mol. Immunol. 31 (13): 977–82. doi:10.1016/0161-5890(94)90092-2. PMID 8084338.
- Chirmule N, Wang XP, Hu R, et al. (1994). “Envelope glycoproteins of HIV-1 interfere with T-cell-dependent B cell differentiation: role of CD4-MHC class II interaction in the effector phase of T cell help”. Cell. Immunol. 155 (1): 169–82. doi:10.1006/cimm.1994.1110. PMID 8168144.
- Callahan KM, Rowell JF, Soloski MJ, et al. (1993). “HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes”. J. Immunol. 151 (6): 2928–42. PMID 8376762.
- Liljedahl M, Kuwana T, Fung-Leung WP, et al. (1996). “HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport”. EMBO J. 15 (18): 4817–24. PMC 452218. PMID 8890155.
- Ruff AL, Guarnieri FG, Staveley-O’Carroll K, et al. (1997). “The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway”. J. Biol. Chem. 272 (13): 8671–8. doi:10.1074/jbc.272.13.8671. PMID 9079699.
- Douek DC, Altmann DM (1997). “HLA-DO is an intracellular class II molecule with distinctive thymic expression”. Int. Immunol. 9 (3): 355–64. doi:10.1093/intimm/9.3.355. PMID 9088974.